Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.
A private biopharmaceutical company .
Visus Therapeutics is a clinical-stage company developing innovative medicines.
Encoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.
Nuance Biotech is a pharmaceutical company Based In China.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Attune Pharmaceuticals is a private biotechnology company.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics.
RTW Investments has invested in 107 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RTW Investments's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Biopharma. The firm invests across 12 different industry categories.
Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. RTW Investments's total known invested capital is $13.3B.
RTW Investments's average investment size is $131.3M across its portfolio of 107 companies.
Recent RTW Investments portfolio additions include Abdera Therapeutics, ACELYRIN, CinCor Pharma, Science 37, Neurogastrx. These companies were founded in 2020 or later.